CNBX (CNBX Pharmaceuticals) Dividends per Share : $0.00 (TTM As of Feb. 2025)

View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals Dividends per Share?

CNBX Pharmaceuticals's dividends per share for the three months ended in Feb. 2025 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Feb. 2025 was $0.00. Its Dividend Payout Ratio for the three months ended in Feb. 2025 was 0.00. As of today, CNBX Pharmaceuticals's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

CNBX Pharmaceuticals Dividends per Share Historical Data

The historical data trend for CNBX Pharmaceuticals's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals Dividends per Share Chart

CNBX Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Dividends per Share

Get a 7-Day Free Trial

CNBX Pharmaceuticals Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of CNBX Pharmaceuticals's Dividends per Share

For the Biotechnology subindustry, CNBX Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CNBX Pharmaceuticals's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's Dividend Yield % falls into.

Save Embed

;

Save Embed

;

CNBX Pharmaceuticals Dividends per Share Calculation

Dividends paid to per common share.

CNBX Pharmaceuticals (OTCPK:CNBX) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

CNBX Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Feb. 2025 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Feb. 2025 )	/	EPS without NRI (Q: Feb. 2025 )
	=	0	/	0
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

CNBX Pharmaceuticals Dividends per Share Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CNBX Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814

Website

https://www.cnbxpharma.com

CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.

Executives

Cannabics Inc.	10 percent owner	108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills	director, officer: President, CEO, CFO
North American Mining Corp	10 percent owner	6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford	director, officer: Vice-President, Secretary